0.00Open0.10Pre Close0 Volume1.97K Open Interest47.50Strike Price0.00Turnover1221.94%IV15.67%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0521Delta0.0241Gamma562.10Leverage Ratio-13.8309Theta0.0000Rho-29.29Eff Leverage0.0004Vega
Sanofi Stock Discussion
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
As reported by Forbes. The Novavax updated vaccine is much superior to the the moderna and Pfizer. It creates 48x antibodies while Moderna and Pfizer created 7x or 8x only.
Why? The answer is imprinting. Once you get a shot of Wuhan mRNA vaccine the body remembers it and will always produce antibodies agai...
"We’re all in on AI. We want to become the first biopharma company powered by AI at scale" -
"We invest in AI that makes a difference for our people, patients, and partners" - #sanofi
Novavax
- 2021 Gets $1.6 billion government grant to develop its COVID shot
- Stock soars over $280
- 2024 - Sanofi is taking a 4.9% equity position in Novavax with 1.2 billion dollar deal with $500 Million up front.
- Malaria WHO Approved & rolled...
The Paris Olympics have signed on 79 sponsors, including 15 Global Partners like $Anheuser-Busch Inbev (BUD.US)$, ...
NVAX closed Monday at $16, down 11.9% for the day and 32.9% from the $23.86 19-month intraday high that it hit last Thursday.
Prior to the recent sell-off, Novavax had gained 438.6% between its $4.43 intraday low on May 9 and its $23.86 intraday peak on...
Alright, folks, let’s dive into the world of biotech drama. Shares of Novavax (NVAX) have been on a tear, continuing their climb on Monday after the company dropped some major news last week. They announced a licensing deal with Sanofi, and the stock shot up 47.6%, closing at $13.11. That's the highest it's been since December 2022.
But wait, there's more! Novavax shares had already doubled last Friday on this news, and over the past three months, t...
MACRO
This week, investors can expect macroeconomic data prints in the form of PPI on Tuesday, and CPI prints Wednesd...
👉 Key Highlights:
📍 Novavax's shares jump 120% in premarket trading after announcing a deal with Sanofi.
📍 Partnership to co-commercialize Covid vaccine and develop combination flu shots.
📍 Sanofi to make an upfront payment of $500 million to Novavax, with potential for up to $700 million more.
📍 Deal includes royalties and up to $200 million in additional milestones.
📍 Sanofi acquires less than ...
No comment yet